ClinicalTrials.gg
CompletedNCT06133400MATAEAUpdated Nov 18, 2023

Mapping the Health Status of the Population of French Polynesia: the MATAEA Project

An interventional study of Questionnaire and Physical measurements in Non Communicable Diseases, Microbiome and Communicable Diseases, sponsored by Institut Louis Malardé. Completed at 1 site in French Polynesia. Open to participants aged 18 Years to 69 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Institut Louis Malardé · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Nov 2019, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,942
Allocation
Not applicable
Ages
18 Years to 69 Years
Sex
All
01

Study summary

This is a cross-sectional study carried out on a sample of the adult population aged 18 to 69, distributed over the five archipelagos of French Polynesia.

Participation in the study involves: agreement to answer a questionnaire to collect information on socio-demographic characteristics, lifestyle habits and medical history; physical measurements (height, weight, waist circumference, blood pressure and skin pigmentation); and agreement to take biological samples (blood, saliva and stool) for biological, genetic and microbiological analyses.

The aim of the study is to assess the current health status of the population of French Polynesia and to evaluate the influence of contextual risk factors (lifestyle, place of residence, history of infection) and intrinsic susceptibility factors (genetics, age, gender, microbiota) in relation to non-communicable and infectious diseases.

02

Conditions studied

  • Non Communicable Diseases
  • Microbiome
  • Communicable Diseases
  • Pesticide Exposure
  • Metal Poison
  • Genetics Population
  • Ciguatera

Keywords

  • cross-sectional survey
  • non-communicable disease
  • communicable disease
  • French Polynesia
  • population genetics
03

In context

Noncommunicable Diseases

146 studies on the registry are indexed under Noncommunicable Diseases; 57 are open to participants now.

This study's enrollment of 1,942 is above the median of 478 across 97 interventional studies indexed under Noncommunicable Diseases.

Browse Noncommunicable Diseases studies →

Lead sponsor

This is the only study on the registry with Institut Louis Malardé as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be aged 18 or over and under 70 on the date of recruitment
  • having signed the consent form

Exclusion criteria

Exclusion Criteria:

  • Minors
  • Pregnant or parturient women, and nursing mothers
  • Persons deprived of their liberty by a judicial or administrative decision
  • Adults who are the subject of a legal protection measure or who are unable to express their consent
  • People undergoing psychiatric care
  • Individuals who are not affiliated to a social security scheme or beneficiaries of such a scheme
  • Homeless people
  • Disabled people (unable to move)
  • People unable to answer the questionnaire
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,942 participants (actual)

Study arms

  • Experimental
    Subjects representative of the adult population (18-69 y) of French Polynesia

    Population sample composed of people aged 18 to 69. These people must have been living in French Polynesia for more than two years at the time of the 2017 census

    Other: Questionnaire · Other: Physical measurements · Other: Biological samples

Interventions

  • OtherQuestionnaire

    Questionnaire about socio-demographical status, health status and lifestyle habits

  • OtherPhysical measurements

    Measurement of height, weight, waist circumference, blood pressure and skin pigmentation

  • OtherBiological samples

    Collect venous blood, saliva and stool samples

06

What researchers measure

Primary outcomes

  1. Prevalence of obesity

    Proportion of participants with indicators of obesity based on physical measurements (BMI, waist circumference) and quantification of lipid levels from blood samples.

    Time frame: 2 years

  2. Prevalence of diabetes

    Proportion of participants with indicators of diabetes based on self-reported data on diabetes history (previous diagnosis, antidiabetic treatment) and quantification of glycated haemoglobin from blood samples.

    Time frame: 2 years

  3. Prevalence of cardiovascular diseases

    Proportion of participants with indicators of cardiovascular diseases based on self-reported data on history of hypertension (previous diagnosis, treatment for hypertension), blood pressure measurement, and quantification of lipid levels from blood samples.

    Time frame: 2 years

  4. Association between non-communicable diseases and behavioral factors

    Calculation of odd ratios to investigate association between non-communicable diseases (obesity, diabetes, cardiovascular diseases) and behavioral factors such as tobacco smoking, alcohol consumption, diet or physical activity data self-reported by the participants in the questionnaire.

    Time frame: 2 years

  5. Association between non-communicable diseases and physical measurements

    Calculation of odd ratios to investigate association between non-communicable diseases (obesity, diabetes, cardiovascular diseases) and physical measurements such as BMI (based on the BMI formula i.e., weight in kilograms divided by height in meters squared).

    Time frame: 2 years

  6. Association between non-communicable diseases and blood analyses

    Calculation of odd ratios to investigate association between non-communicable diseases (obesity, diabetes, cardiovascular diseases) and blood analyses (such as glycated haemoglobin and lipid levels).

    Time frame: 2 years

  7. Seroprevalence of communicable diseases

    Proportion of participants with IgG antibodies, detected in blood samples, specific for different pathogens : arboviruses (four dengue serotypes, Zika, chikungunya), hepatitis B and C viruses, hantaviruses, SARS-CoV-2 and other pathogens known to regularly cause infections in French Polynesia (including influenza viruses, human immunodeficiency virus...). Proportion of participants with positive filarial antigenemia to assess the prevalence of Bancroftian lymphatic filariasis.

    Time frame: 2 years

  8. Composition of microbiome

    Bacterial DNA sequencing from stool and saliva samples to assess the gut and oral microbiota profiles and association with lifestyle behavior, diet and susceptibility to communicable and non-communicable diseases.

    Time frame: 2 years

  9. Level of exposure to heavy metals

    Quantification of levels of heavy metals (including mercury and lead) from blood samples and association with lifestyle behavior and diet.

    Time frame: 2 years

  10. Level of exposure to pesticides

    Quantification of levels of pesticides (including chlordane and toxaphene) from blood samples and association with lifestyle behavior and diet.

    Time frame: 2 years

  11. Level of exposure to mosquito bites

    Proportion of participants with IgG antibodies targeting mosquito salivary proteins in blood samples to assess the risk of infection by mosquito-borne viruses

    Time frame: 2 years

  12. Prevalence of ciguatera poisoning

    Estimation of the rate of ciguatera poisoning in the population based on data self-reported by the participants in the questionnaire e.g. the occurrence of symptoms suggestive for ciguatera poisoning at least once in their lifetime

    Time frame: 2 years

  13. Demographic and adaptive history of French Polynesians using genomics

    Human Whole Genome Sequencing from saliva samples to reconstruct the genetic history of the population of French Polynesia, in terms of both demographic and adaptive history.

    Time frame: 2 years

  14. Genetic susceptibility to obesity

    Genome-wide association studies to identify human genetic factors that are associated with BMI or lipids levels.

    Time frame: 2 years

  15. Genetic susceptibility to diabetes

    Genome-wide association studies to identify human genetic factors that are associated with HbA1c.

    Time frame: 2 years

  16. Genetic susceptibility to communicable diseases

    Genome-wide association studies to identify human genetic factors that are associated with the detection of IgG antibodies specific for different pathogens: arboviruses, hepatitis B and C viruses, hantaviruses, SARS-CoV-2 and other pathogens known to regularly cause infections in French Polynesia (including influenza viruses, human immunodeficiency virus...).

    Time frame: 2 years

07

Study locations

1 site
  • Institut Louis Malardé
    Papeete, Tahiti 98713, French Polynesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Dec 2021, 25 months.

Of 79 non-industry interventional studies with no phase under Noncommunicable Diseases, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 25 months is above that.

Counting every sponsor, half of 79 studies reached it within 17 months; a quarter within 7 and three quarters within 30.

Noncommunicable Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Nov 15, 2023
StartActual
Nov 4, 2019
Primary completionActual
Dec 8, 2021
CompletionActual
Dec 8, 2021
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06133400
Lead sponsor
Institut Louis Malardé
Collaborators
Institut Pasteur, Institut de la Statistique de la Polynésie française, Centre Hospitalier de la Polynésie française, Université de la Polynésie française, Institut National en Santé Publique du Québec
Responsible party
Sponsor
First posted
Nov 15, 2023
Start date
Nov 4, 2019
Primary completion
Dec 8, 2021
Completion
Dec 8, 2021
Last update
Nov 18, 2023

Study contacts

Van-Mai CAO-LORMEAU, PhD
study director · Institut Louis Malardé

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion